- Home
- ELDN vs TLSI Comparison
ELDN vs TLSI Comparison
Compare ELDN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- TLSI
- Stock Information
- Founded
- ELDN 2004
- TLSI 2010
- Country
- ELDN United States
- TLSI United States
- Employees
- ELDN N/A
- TLSI N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- ELDN Health Care
- TLSI Health Care
- Exchange
- ELDN Nasdaq
- TLSI Nasdaq
- Market Cap
- ELDN 178.4M
- TLSI 160.4M
- IPO Year
- ELDN N/A
- TLSI N/A
- Fundamental
- Price
- ELDN $2.89
- TLSI $5.02
- Analyst Decision
- ELDN Strong Buy
- TLSI Strong Buy
- Analyst Count
- ELDN 1
- TLSI 6
- Target Price
- ELDN $16.00
- TLSI $11.75
- AVG Volume (30 Days)
- ELDN 160.2K
- TLSI 33.4K
- Earning Date
- ELDN 05-20-2025
- TLSI 05-14-2025
- Dividend Yield
- ELDN N/A
- TLSI N/A
- EPS Growth
- ELDN N/A
- TLSI N/A
- EPS
- ELDN N/A
- TLSI N/A
- Revenue
- ELDN N/A
- TLSI $29,431,000.00
- Revenue This Year
- ELDN N/A
- TLSI $56.00
- Revenue Next Year
- ELDN N/A
- TLSI $52.17
- P/E Ratio
- ELDN N/A
- TLSI N/A
- Revenue Growth
- ELDN N/A
- TLSI 58.99
- 52 Week Low
- ELDN $2.00
- TLSI $3.50
- 52 Week High
- ELDN $5.54
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- ELDN 40.93
- TLSI 34.87
- Support Level
- ELDN $2.85
- TLSI $4.66
- Resistance Level
- ELDN $3.51
- TLSI $5.40
- Average True Range (ATR)
- ELDN 0.27
- TLSI 0.37
- MACD
- ELDN -0.01
- TLSI -0.06
- Stochastic Oscillator
- ELDN 5.63
- TLSI 29.51
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.